These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8174116)

  • 1. Clinical pharmacology of hepatic arterial infusions of 5-bromo-2'-deoxyuridine.
    Ensminger WD; Walker SC; Stetson PL; Wagner JG; Knol JA; Lawrence TS; Andrews JC
    Cancer Res; 1994 Apr; 54(8):2121-4. PubMed ID: 8174116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions.
    Kuan HY; Smith DE; Ensmiger WD; Knol JA; DeRemer SJ; Yang Z; Stetson PL
    Cancer Res; 1996 Oct; 56(20):4724-7. PubMed ID: 8840990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporation of 5-bromo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion.
    Knol JA; Walker SC; Robertson JM; Yang Z; DeRemer S; Stetson PL; Ensminger WD; Lawrence TS
    Cancer Res; 1995 Sep; 55(17):3687-91. PubMed ID: 7641176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs.
    Wollner IS; Knutsen CA; Ullrich KA; Chrisp CE; Juni JE; Andrews JC; Tuscan MJ; Stetson PL; Ensminger WD
    Cancer Res; 1987 Jun; 47(12):3285-90. PubMed ID: 3581069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic arterial BCNU: a pilot clinical-pharmacologic study in patients with liver tumors.
    Ensminger WD; Thompson M; Come S; Egan EM
    Cancer Treat Rep; 1978 Oct; 62(10):1509-12. PubMed ID: 709552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
    Bhargava P; Marshall JL; Dahut W; Rizvi N; Trocky N; Williams JI; Hait H; Song S; Holroyd KJ; Hawkins MJ
    Clin Cancer Res; 2001 Dec; 7(12):3912-9. PubMed ID: 11751482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors.
    Russo A; Gianni L; Kinsella TJ; Klecker RW; Jenkins J; Rowland J; Glatstein E; Mitchell JB; Collins J; Myers C
    Cancer Res; 1984 Apr; 44(4):1702-5. PubMed ID: 6704976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer.
    Aldrighetti L; Arru M; Ronzoni M; Salvioni M; Villa E; Ferla G
    Hepatogastroenterology; 2001; 48(41):1302-7. PubMed ID: 11677951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma.
    Ueno H; Okada S; Okusaka T; Ikeda M; Kuriyama H
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):155-60. PubMed ID: 11862430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
    Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation.
    van Iersel LB; Verlaan MR; Vahrmeijer AL; van Persijn van Meerten EL; Tijl FG; Sparidans RW; Gelderblom H; Kuppen PJ; Tollenaar RA; van de Velde CJ
    Eur J Surg Oncol; 2007 Sep; 33(7):874-81. PubMed ID: 17400422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.
    Wagner JG; Gyves JW; Stetson PL; Walker-Andrews SC; Wollner IS; Cochran MK; Ensminger WD
    Cancer Res; 1986 Mar; 46(3):1499-506. PubMed ID: 3943107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
    Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
    Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
    Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Continuous hepatic arterial infusion chemotherapy with low-dose CDDP plus 5-FU for liver metastases from colorectal carcinoma].
    Kohnoe S; Taketomi A; Morita M; Baba H; Matsuoka H; Seo Y; Saito T; Tomoda H
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1429-32. PubMed ID: 8854771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.